| Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients. | |
| | |
MedLine Citation:
|
PMID: 16997061 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Recommendations for the management of left ventricular (LV) systolic dysfunction in the general population and patients with end-stage renal disease (ESRD) include the use of angiotensin-converting enzyme (ACE) inhibitors and beta-blockers. Limited data from the literature suggest that these pharmacological agents may be underused in patients with ESRD. The goal of this study is to describe the use of these medications and investigate barriers to their use in dialysis patients. METHODS: We prospectively studied 420 hemodialysis patients. Diagnosis of systolic dysfunction was based on echocardiogram results. Use of cardiac medication was recorded for all patients with systolic dysfunction, and a questionnaire was administered to nephrologists to determine the basis for decisions concerning ACE-inhibitors and beta-blockers use/nonuse. RESULTS: Forty-seven patients (11%) were found to have an LV ejection fraction of 40% or less. Of those, 72% were administered a beta-blocker and 36% were administered an ACE inhibitor. Only 12 patients (25.5%) were administered a combination of beta-blocker and ACE inhibitor. Reasons indicated by nephrologists for not prescribing these medications were "concern about adverse reactions (eg, hypotension, hyperkalemia)" in 88% of cases, "adequate control of symptoms with ultrafiltration" in 38%, "unproven benefit" in 25%, and "unfavorable risk-benefit ratio" in 17%. Medication costs and concern about patient compliance were not identified as significant concerns by physicians. CONCLUSION: Only 25.5% of patients with ESRD with LV systolic dysfunction receive appropriate treatment. Concern regarding adverse reactions was the most frequent reason indicated by nephrologists for not prescribing ACE inhibitors and beta-blockers. |
| | |
Authors:
|
Patrick Roy; Josée Bouchard; Robert Amyot; François Madore |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: American journal of kidney diseases : the official journal of the National Kidney Foundation Volume: 48 ISSN: 1523-6838 ISO Abbreviation: Am. J. Kidney Dis. Publication Date: 2006 Oct |
Date Detail:
|
Created Date: 2006-09-25 Completed Date: 2006-10-12 Revised Date: 2008-11-21 |
Medline Journal Info:
|
Nlm Unique ID: 8110075 Medline TA: Am J Kidney Dis Country: United States |
Other Details:
|
Languages: eng Pagination: 645-51 Citation Subset: IM |
Affiliation:
|
Nephrology Division, Hôpital du Sacré-Coeur de Montréal, Université de Montréal, Montréal, Québec, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
adverse effects,
therapeutic use* Aged Aged, 80 and over Angiotensin-Converting Enzyme Inhibitors / adverse effects, therapeutic use* Drug Prescriptions / statistics & numerical data* Female Humans Kidney Failure, Chronic / complications, therapy* Male Middle Aged Physician's Practice Patterns / statistics & numerical data* Prevalence Prospective Studies Quebec Questionnaires Renal Dialysis* Risk Assessment Stroke Volume / drug effects Ventricular Dysfunction, Left / drug therapy*, etiology |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Sestamibi scintigraphy, topography, and histopathology of parathyroid glands in secondary hyperparat...
Next Document: Percutaneous treatment of dysfunctional Brescia-Cimino fistulae through a radial arterial approach.